Plant Name: Aframomum amaniense
Taxonomic Information:
Plant ID: NPO6179
Plant Latin Name: Aframomum amaniense
Taxonomy Genus: Aframomum
Taxonomy Family: Zingiberaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| RECQL; TDP1; TERT; GLO1; HPGD; PGD; ALOX12; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| BCL2; | |
| TOP2A; | |
| TEK; KDR; MET; AXL; FLT3; CDK1; EGFR; PIM1; NUAK1; SRC; INSR; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| TYR; | |
| KDM4E; | |
| F10; F2; | |
| AHR; | |
| FUT7; | |
| DNMT1; | |
| ABCB1; | |
| SLC22A6; | |
| LMNA; SMAD3; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.858E-09 | 2.588E-06 | AXL, EGFR, F10, INSR, MET, NOX4, SRC, TEK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.493E-08 | 7.869E-06 | ABCB1, AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.235E-08 | 1.676E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.635E-07 | 3.632E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.911E-07 | 9.141E-05 | ACHE, BCL2, CDK1, CYP1A1, EGFR, F2, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.108E-07 | 9.426E-05 | AKR1B1, ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, KDM4E, NOX4, PGD, TYR |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.162E-07 | 1.082E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.346E-06 | 2.109E-04 | BCL2, CA2, CA7, F2, KDR, NPSR1, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.528E-06 | 2.360E-04 | EGFR, INSR, KDR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.856E-06 | 2.750E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.179E-06 | 3.163E-04 | ABCB1, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.179E-06 | 3.163E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 2.581E-06 | 3.649E-04 | BCL2, NOX4, SRC, TERT |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.581E-06 | 3.649E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.853E-06 | 7.916E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.412E-06 | 8.453E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.108E-06 | 9.159E-04 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 9.466E-06 | 1.151E-03 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, SMAD3, SRC |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.036E-05 | 1.240E-03 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.048E-05 | 1.247E-03 | AHR, AXL, BCL2, CSNK2A1, EGFR, SRC, TOP2A |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.439E-05 | 1.640E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.546E-05 | 1.736E-03 | CDK1, CYP1A2, EGFR, TERT |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.682E-05 | 1.859E-03 | AKR1B1, HPGD, HSD17B10, HSD17B2, PGD |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.905E-05 | 2.043E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 2.250E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.365E-05 | 2.464E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.392E-05 | 2.481E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 2.578E-05 | 2.644E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 2.975E-05 | 2.985E-03 | F2, FLT3, KDR, TEK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.137E-05 | 3.092E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.137E-05 | 3.092E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.250E-05 | 3.872E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 4.893E-05 | 4.314E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 5.090E-05 | 4.470E-03 | ACHE, AKR1B1, APEX1, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 5.191E-05 | 4.504E-03 | AKR1B1, EGFR, HPGD, TERT |
| BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 5.465E-05 | 4.703E-03 | AKR1B1, CYP1B1, F2, FLT3 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.563E-05 | 4.769E-03 | AHR, AKR1B1, APEX1, AURKB, BCL2, CDK1, CSNK2A1, DNMT1, HPGD, HSPA1A, L3MBTL1, LMNA, NUAK1, PIM1, POLB, RECQL, SMAD3, SRC, TERT, TOP2A |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 5.799E-05 | 4.952E-03 | ALOX12, CYP1B1, KDR, TEK, TERT |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 6.399E-05 | 5.319E-03 | AXL, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 7.097E-05 | 5.702E-03 | FLT3, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 7.401E-05 | 5.903E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 8.048E-05 | 6.236E-03 | ACHE, EGFR, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.637E-05 | 6.646E-03 | AHR, CSNK2A1, KDR |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1.038E-04 | 7.637E-03 | BCL2, HSPA1A, TERT |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.059E-04 | 7.695E-03 | ALOX12, HPGD |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.064E-04 | 7.695E-03 | BCL2, CA2, EGFR, MET, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:1900087; positive regulation of G1/S transition of mitotic cell cycle | 1.234E-04 | 8.781E-03 | APEX1, CYP1A1, TERT |
| BP | Unclassified; | GO:0006461; protein complex assembly | 1.283E-04 | 8.980E-03 | ACHE, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, SLC22A6, SMAD3, SRC, TEK, TERT |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 1.292E-04 | 9.016E-03 | APEX1, NOX4, TEK, TYR |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.311E-04 | 9.121E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.399E-04 | 9.591E-03 | CDK1, EGFR, F2, SMAD3 |
| BP | GO:0009987; cellular process | GO:0045930; negative regulation of mitotic cell cycle | 1.464E-04 | 9.825E-03 | AURKB, BCL2, CDK1, EGFR, SMAD3, TOP2A |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.480E-04 | 9.825E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.480E-04 | 9.825E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 8.315E-10 | 1.156E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.892E-07 | 8.764E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.178E-06 | 4.093E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.429E-08 | 6.553E-06 | CA12, CA2, CA4, CA7 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.583E-06 | 1.274E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.045E-06 | 1.632E-04 | INSR, BCL2, TEK, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.120E-05 | 2.224E-04 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, MET, EGFR |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.363E-05 | 2.368E-04 | SRC, KDR, BCL2, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.726E-05 | 3.445E-04 | INSR, KDR, BCL2, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.634E-05 | 3.445E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.554E-05 | 2.400E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.809E-04 | 1.934E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.546E-04 | 5.139E-03 | SMAD3, FLT3, BCL2, MET, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.530E-04 | 1.773E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.952E-04 | 3.923E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.175E-04 | 5.365E-03 | INSR, HSPA1A, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.167E-03 | 7.676E-03 | DNMT1, FUT7, HSD17B2, CYP1A2, CYP1A1, AKR1B1, ALOX12, PGD, TYR, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.062E-04 | 5.694E-03 | FLT3, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.374E-04 | 5.694E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.364E-04 | 6.119E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.226E-03 | 7.676E-03 | HPGD, FLT3, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.068E-04 | 6.302E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.872E-03 | 9.638E-03 | CSNK2A1, BCL2, CDK1, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.608E-03 | 8.660E-03 | BCL2, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.557E-03 | 8.660E-03 | SRC, CDK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.270E-03 | 7.676E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.620E-03 | 8.660E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; EGFR; ABCB1; |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Haemophilia B | NA | F10; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; EGFR; SRC; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; INSR; EGFR; BCL2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; EGFR; SRC; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; TYR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; ABCB1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; DNMT1; EGFR; SRC; ABCB1; F2; BCL2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| NA: NA | Christmas disease | NA | F10; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; F2; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; SRC; BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| NA: NA | Edema | NA | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; ABCB1; F2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; DNMT1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; BCL2; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; EGFR; BCL2; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; BCL2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; DNMT1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
